179 related articles for article (PubMed ID: 15894326)
1. Assays for the assessment of neutralizing antibody activities against Severe Acute Respiratory Syndrome (SARS) associated coronavirus (SCV).
Wang S; Sakhatskyy P; Chou TH; Lu S
J Immunol Methods; 2005 Jun; 301(1-2):21-30. PubMed ID: 15894326
[TBL] [Abstract][Full Text] [Related]
2. SARS patients-derived human recombinant antibodies to S and M proteins efficiently neutralize SARS-coronavirus infectivity.
Liang MF; Du RL; Liu JZ; Li C; Zhang QF; Han LL; Yu JS; Duan SM; Wang XF; Wu KX; Xiong ZH; Jin Q; Li DX
Biomed Environ Sci; 2005 Dec; 18(6):363-74. PubMed ID: 16544518
[TBL] [Abstract][Full Text] [Related]
3. Protection of mammalian cells from severe acute respiratory syndrome coronavirus infection by equine neutralizing antibody.
Wang X; Ni B; Du X; Zhao G; Gao W; Shi X; Zhang S; Zhang L; Wang D; Luo D; Xing L; Jiang H; Li W; Jiang M; Mao L; He Y; Xiao Y; Wu Y
Antivir Ther; 2005; 10(5):681-90. PubMed ID: 16152762
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a novel vesicular stomatitis virus pseudotype-based assay for detection of neutralizing antibody responses to SARS-CoV.
Fukushi S; Mizutani T; Saijo M; Kurane I; Taguchi F; Tashiro M; Morikawa S
J Med Virol; 2006 Dec; 78(12):1509-12. PubMed ID: 17063504
[TBL] [Abstract][Full Text] [Related]
5. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D
Nature; 2020 Jul; 583(7815):290-295. PubMed ID: 32422645
[TBL] [Abstract][Full Text] [Related]
6. An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies.
Zhou T; Wang H; Luo D; Rowe T; Wang Z; Hogan RJ; Qiu S; Bunzel RJ; Huang G; Mishra V; Voss TG; Kimberly R; Luo M
J Virol; 2004 Jul; 78(13):7217-26. PubMed ID: 15194798
[TBL] [Abstract][Full Text] [Related]
7. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines.
He Y; Zhu Q; Liu S; Zhou Y; Yang B; Li J; Jiang S
Virology; 2005 Mar; 334(1):74-82. PubMed ID: 15749124
[TBL] [Abstract][Full Text] [Related]
8. Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes.
Temperton NJ; Chan PK; Simmons G; Zambon MC; Tedder RS; Takeuchi Y; Weiss RA
Emerg Infect Dis; 2005 Mar; 11(3):411-6. PubMed ID: 15757556
[TBL] [Abstract][Full Text] [Related]
9. Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections.
Lv H; Wu NC; Tsang OT; Yuan M; Perera RAPM; Leung WS; So RTY; Chan JMC; Yip GK; Chik TSH; Wang Y; Choi CYC; Lin Y; Ng WW; Zhao J; Poon LLM; Peiris JSM; Wilson IA; Mok CKP
Cell Rep; 2020 Jun; 31(9):107725. PubMed ID: 32426212
[TBL] [Abstract][Full Text] [Related]
10. Molecular targets for diagnostics and therapeutics of severe acute respiratory syndrome (SARS-CoV).
Suresh MR; Bhatnagar PK; Das D
J Pharm Pharm Sci; 2008 Apr; 11(2):1s-13s. PubMed ID: 19203466
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): identification of neutralizing and antibodies reactive to S, N, M and E viral proteins.
Tripp RA; Haynes LM; Moore D; Anderson B; Tamin A; Harcourt BH; Jones LP; Yilla M; Babcock GJ; Greenough T; Ambrosino DM; Alvarez R; Callaway J; Cavitt S; Kamrud K; Alterson H; Smith J; Harcourt JL; Miao C; Razdan R; Comer JA; Rollin PE; Ksiazek TG; Sanchez A; Rota PA; Bellini WJ; Anderson LJ
J Virol Methods; 2005 Sep; 128(1-2):21-8. PubMed ID: 15885812
[TBL] [Abstract][Full Text] [Related]
12. Antibody-mediated synergy and interference in the neutralization of SARS-CoV at an epitope cluster on the spike protein.
Zhong L; Haynes L; Struble EB; Tamin A; Virata-Theimer ML; Zhang P
Biochem Biophys Res Commun; 2009 Dec; 390(3):1056-60. PubMed ID: 19861118
[TBL] [Abstract][Full Text] [Related]
13. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins.
Wang SF; Tseng SP; Yen CH; Yang JY; Tsao CH; Shen CW; Chen KH; Liu FT; Liu WT; Chen YM; Huang JC
Biochem Biophys Res Commun; 2014 Aug; 451(2):208-14. PubMed ID: 25073113
[TBL] [Abstract][Full Text] [Related]
14. Development of a safe neutralization assay for SARS-CoV and characterization of S-glycoprotein.
Han DP; Kim HG; Kim YB; Poon LL; Cho MW
Virology; 2004 Aug; 326(1):140-9. PubMed ID: 15262502
[TBL] [Abstract][Full Text] [Related]
15. Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system.
Wang S; Chou TH; Sakhatskyy PV; Huang S; Lawrence JM; Cao H; Huang X; Lu S
J Virol; 2005 Feb; 79(3):1906-10. PubMed ID: 15650214
[TBL] [Abstract][Full Text] [Related]
16. Antibody-dependent enhancement of SARS coronavirus infection and its role in the pathogenesis of SARS.
Yip MS; Leung HL; Li PH; Cheung CY; Dutry I; Li D; Daëron M; Bruzzone R; Peiris JS; Jaume M
Hong Kong Med J; 2016 Jun; 22(3 Suppl 4):25-31. PubMed ID: 27390007
[No Abstract] [Full Text] [Related]
17. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies.
He Y; Lu H; Siddiqui P; Zhou Y; Jiang S
J Immunol; 2005 Apr; 174(8):4908-15. PubMed ID: 15814718
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine.
Qin E; Shi H; Tang L; Wang C; Chang G; Ding Z; Zhao K; Wang J; Chen Z; Yu M; Si B; Liu J; Wu D; Cheng X; Yang B; Peng W; Meng Q; Liu B; Han W; Yin X; Duan H; Zhan D; Tian L; Li S; Wu J; Tan G; Li Y; Li Y; Liu Y; Liu H; Lv F; Zhang Y; Kong X; Fan B; Jiang T; Xu S; Wang X; Li C; Wu X; Deng Y; Zhao M; Zhu Q
Vaccine; 2006 Feb; 24(7):1028-34. PubMed ID: 16388880
[TBL] [Abstract][Full Text] [Related]
19. SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus.
Woo PC; Lau SK; Tsoi HW; Chen ZW; Wong BH; Zhang L; Chan JK; Wong LP; He W; Ma C; Chan KH; Ho DD; Yuen KY
Vaccine; 2005 Oct; 23(42):4959-68. PubMed ID: 15993989
[TBL] [Abstract][Full Text] [Related]
20. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model.
Du L; Zhao G; He Y; Guo Y; Zheng BJ; Jiang S; Zhou Y
Vaccine; 2007 Apr; 25(15):2832-8. PubMed ID: 17092615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
